{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-002915","form_type":"8-K","ticker":"ITGR","cik":"0001114483","company_name":"Integer Holdings Corp","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.796970+00:00","generated_at":"2026-06-26T03:07:52.651996+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Integer Q1 sales up 7% to $311M, adjusted EPS down 20%; guidance raised for Aran Biomedical acquisition","bullets":["Sales $311M (+7% YoY); GAAP net income $11M (-47%); adjusted net income $26M (-19%).","GAAP diluted EPS $0.34; non-GAAP adjusted EPS $0.78, down 20% YoY.","Acquired Aran Biomedical on April 6, 2022; adds ~$90M annualized sales at accretive growth.","FY2022 outlook: sales $1.36-1.38B (11-13% growth), adj. EBITDA $273-285M (12-17% growth).","Cardio & Vascular sales +13%; Cardiac Rhythm +1%; Electrochem +18%; Advanced Surgical -2%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-002915","json":"https://secwatch.observer/filing/0001171843-22-002915.json","markdown":"https://secwatch.observer/filing/0001171843-22-002915.md","text":"https://secwatch.observer/filing/0001171843-22-002915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322002915/0001171843-22-002915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114483/000117184322002915/f8k_042822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:07:52.651996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}